IMMUTEP LIMITED — Board/Management Information 2009

Nov 22, 2009

==> picture [181 x 49] intentionally omitted <==

ASX/Media Release 23 November 2009

DR NEIL FRAZER APPOINTED CHIEF MEDICAL OFFICER TO OVERSEE CLINICAL TRIALS FOR CVac™ OVARIAN CANCER VACCINE

Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce the appointment of international pharmaceutical industry expert Dr Neil Frazer as the Company’s Chief Medical Officer to oversee Prima’s key upcoming clinical trials for its headline product, the CVac™ ovarian cancer vaccine treatment.

Dr Frazer will be contracted with Fulcrum Pharma Developments Inc full time. Dr Frazer will be based in the United States, where he will be responsible for overseeing CVac™’s upcoming Phase IIb Pivotal Clinical Trial with the United States Food and Drug Administration (FDA), and also for the Phase III trial in Europe which will commence next year.

This represents a key senior appointment for the Company as it embarks on its clinical trials which is the next major step in the commercialisation process for CVac™ into the multi-billion global pharmacy oncology market.

Dr Frazer has more than 23 years experience in the pharmaceutical industry and has a strong depth of expertise in managing the clinical development process of new drug applications.

He has been involved in the successful applications for 10 new chemical entities in multiple therapeutic areas and over 20 applications for line extensions of pharmaceutical drug applications. Also, importantly, he has a high level of expertise in the FDA’s Investigational New Drug (IND) planning, submission and reviewing process, which is the designation Prima is seeking for CVac™.

In his new role with Prima, Dr Frazer will be responsible for providing medical expertise for the Company’s clinical programs. He will direct clinical development of Prima’s cancer vaccine drug candidates and help facilitate their approval with relevant international government agencies. He will contribute to peer-reviewed manuscripts in the oncology therapeutic area and liaise regularly with oncology physicians to continue CVac™’s IND process and develop the cancer vaccine for commercial use.

Prima BioMed executive director Martin Rogers said: “The role of Chief Medical Officer has a worldwide scope and we are delighted to announce the appointment of such a high calibre expert in the field as Dr Neil Frazer. He will lead the clinical development of our cancer vaccine candidates, and will be responsible for ensuring that word’s best Good Clinical Practice, Good Manufacturing Practice and Good Laboratory Practice standards are met.”

Dr Frazer has a Bachelor of Medicine and Bachelor of Surgery (MB ChB) from the University of Edinburgh Medical School, and has a Fellowship from the Royal College of Anaesthetists in London (FRCA) and a Fellowship in Pharmaceutical Medicine from the Royal College of Physicians.

ENDS

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889

For further information please contact:

Mr Martin Rogers James Moses Executive Director Investor and Media Relations Prima BioMed Mandate Corporate Ph: 0428 268 357 Ph: 0420 991 574 E: martin.rogers@primabiomed.com.au E: james@mandatecorporate.com.

Website: www.primabiomed.com.au

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed’s lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b by 2010.

Regulatory approval and commercialisation of CVac™ is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima’s lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889